

### **Remarks**

#### **1. Election/Restrictions**

Applicants thank the Examiner for withdrawing the previously imposed restriction requirement.

#### **2. Sequence Compliance**

The Examiner noted that a sequence listed in the specification was not included in the sequence listing. The sequence listed on page 7, line 7 has been inserted into the sequence listing and a new sequence listing submitted. The listing with the additional sequence does not contain new matter and the paper listing and computer readable form (CRF) are identical.

#### **3. Information Disclosure Statement**

The office action indicated that the previously submitted IDS was not submitted with copies of the references. Applicants believe that copies were provided with the submission but have resubmitted the original IDS and an additional supplemental IDS (that was also previously submitted) with references.

#### **4. Specification**

The abstract of disclosure was objected to because it did not end in a period. The abstract has been corrected.

#### **5. Claim Objections**

Claims 2-9, 12, 16, and 18 were objected to because they did not end in a period. This has been corrected in claims 2-9, 12 and 16. Claim 18 was canceled.

#### **6. Double Patenting**

6. Claims 5-8 were objected to as being a substantial duplicate of claim 9. Claim 9 has been amended.

7. Claim 17 and 18 were objected to as being substantial duplicates. Claim 18 has been canceled.

8. Claim 19 was objected to as being a substantial duplicate of claim 20. Applicants disagree. Claim 19 recites a "tau protein that is labeled" and claim 20 recites a tau protein which "comprises a tag". Page 12 and common usage in the art makes it clear that a "tag" is a peptide extension and therefore is not coextensive with the term "labeled"

9. Claim Rejections 35 USC § 112 –Paragraph 1 Enablement

The Examiner has stated that the claims are enabled for in-vitro cell free methods but not cell cultures. Applicants have amended the claim 1 to facilitate prosecution and obtain early allowance of claims. Applicants reserve the option to pursue the originally claimed subject matter in a continuing application.


10. Claim Rejections 35 USC § 112 –Paragraph 2 Indefinite

Claim 9 was rejected for recitation of the transitional term “comprising”. The claim has been amended.

**Conclusion**

In light of the foregoing it is believed that all claims are in condition for allowance and an early notice of allowance is earnestly requested.

Respectfully submitted,

  
Edward F. Rehberg, Attorney  
Registration No. 34,703

Date: 5-10-04

Pharmacia & Upjohn Company  
Global Intellectual Property  
301 Henrietta Street  
Kalamazoo, Michigan 49001

Telephone No. (616) 833-7829 or (616) 833-9500  
Telefax No. (616) 833-8897 or (616) 833-2316